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 Abstract 
 Obesity and the related diabetes epidemics represent a real concern worldwide. Bariatric/
metabolic surgery emerged in last years as a valuable therapeutic option for obesity and re-
lated diseases, including type 2 diabetes mellitus (T2DM). The complicated network of mecha-
nisms involved in obesity and T2DM have not completely defined yet. There is still a debate on 
which would be the first metabolic defect leading to metabolic deterioration: insulin resistance 
or hyperinsulinemia? Insight into the metabolic effects of bariatric/metabolic surgery has re-
vealed that, beyond weight loss and food restriction, other mechanisms can be activated by 
the rearrangements of the gastrointestinal tract, such as the incretinic/anti-incretinic system, 
changes in bile acid composition and flow, and modifications of gut microbiota; all of them 
possibly involved in the remission of T2DM. The complete elucidation of these mechanisms will 
lead to a better understanding of the pathogenesis of this disease. Our aim was to review some 
of the metabolic mechanisms involved in the development of T2DM in obese patients as well 
as in the remission of this condition in patients submitted to bariatric/metabolic surgery. 
 © 2015 S. Karger GmbH, Freiburg 
 Introduction 
 Obesity has become a real concern worldwide due to its increasing prevalence and to the 
associated cluster of diseases that reduce life quality and expectancy. Patients with BMI over 
40 kg/m² as well as those with a BMI over 35 kg/m² and comorbidities, who have failed to 
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obtain and maintain significant weight reduction through nonsurgical means, are submitted 
to bariatric surgery in order to reach the weight goals  [1] . Type 2 diabetes mellitus (T2DM) 
is the major comorbidity of obesity, and therefore the terms ‘diabesity’ and ‘obesity-dependent 
diabetes’ are often used  [2] . Approximately half of the individuals diagnosed with T2DM are 
obese  [2] .
 Bariatric surgery exerts a complex impact on human body, beyond weight loss, by 
improving metabolic health. Therefore, the term ‘metabolic surgery’ recently has been 
proposed as a more appropriate labelling  [3, 4] . The term ‘metabolic surgery’ was used for 
the first time 35 years ago by Richard L. Varco and Henry Buchwald  [5] , and it was that time 
defined ‘as the operative manipulation of a normal organ or organ system to achieve a 
biological result for a potential health gain’. Indeed, a large body of evidence has demon-
strated that several gastrointestinal operations primarily designed to promote weight loss 
can ameliorate or restore T2DM  [6, 7] . Bariatric/metabolic surgery has been found to be more 
effective than conventional medical therapy in inducing T2DM improvement or remission in 
several randomized and non-randomized controlled trials  [8–12] . It is reasonable to suppose 
that surgical weight loss per se is associated with remission of T2DM. However, rapid improve-
ments in blood glucose levels, occurring within days after surgery long before substantial 
weight loss, initially suggested that other mechanisms beyond weight reduction could be 
involved in these changes  [13] . As explained below, this was not the case, giving that such 
initial improvements may be more simply explained by postoperative caloric restriction, but 
some possible non-weight-loss-related mechanisms are probably involved in graduating the 
metabolic response to different surgical procedures and in maintaining these improvements 
over time. The details have not yet completely understood, but a more complete elucidation 
of the metabolic changes induced by bariatric/metabolic surgery may also bring light upon 
the pathogenesis of T2DM in patients with obesity. Some of the mechanisms involved in the 
development of T2DM in obesity as well as in T2DM remission after bariatric/metabolic 
surgery will be reviewed here. 
 Obesity and Type 2 Diabetes 
 Insulin Resistance or Hyperinsulinemia: Who Is Coming First? 
 T2DM is a heterogeneous disorder most commonly characterized by insulin resistance, 
a state of reduced insulin-mediated glucose uptake, in the presence of incapacity of the 
pancreatic beta cells to produce and provide sufficient insulin to meet the required needs 
 [14] . T2DM may range from insulin resistance with relative insulin deficiency to a secretory 
defect with minimal insulin resistance. The classical view for explaining the development of 
T2DM in obesity states that insulin resistance is the first lesion, followed by hyperinsulinemia, 
and that hyperglycemia occurs as the consequence of beta cell failure to produce enough 
insulin. Insulin resistance in muscle is caused by inherited and environmental factors and is 
the earliest detectable disturbance of T2DM  [15–17] . T2DM is a disease that progresses 
despite glucose-lowering medication, and 50% of the patients require insulin therapy within 
10 years  [18] . 
 More recently, Taylor et al.  [15, 16] proposed the ‘twin cycle hypothesis’ to better explain 
the etiology of T2DM in obese patients ( fig. 1 ). Whole-body insulin resistance is the earliest 
predictor of T2DM onset  [19] . However, hepatic rather than muscle insulin resistance is 
involved in the occurrence of hyperglycemia and overt diabetes  [20] . The pre-existing muscle 
insulin resistance caused by inherited and environmental factors leads to raised plasma insulin 
levels, which, together with an increased caloric overload, will exert accumulation of fat in the 
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liver. In turn, liver fat accumulation causes hepatic insulin resistance, hence the failure of 
insulin to suppress liver glucose production. Consequently, increased plasma glucose as well 
as further increased basal insulin secretion will develop, exacerbating hepatic steatosis. This 
forms the first vicious cycle (the liver cycle). Liver fat infiltration, and related high fatty acid 
turnover, then induces an over-exposure of the beta cells to fatty acids, which will impair the 
acute insulin secretion in response to ingested food and lead to postprandial hyperglycemia. 
Hyperglycemia will further stimulate insulin secretion which will consequently increase liver 
lipogenesis, thus connecting the liver cycle with a new vicious cycle (the pancreas cycle). Note-
worthy, fatty liver is a disturbance that is present years before the T2DM development. A 
history of 2–3 years of T2DM does not produce irreversible damages to the beta cells, but as 
long as the energy overload persists through years, irreversible impairment of the beta cells 
occurs, and insulin is required in order to control plasma glucose  [15, 16] . As outlined below, 
this more complex metabolic view may be of great relevance in explaining the rapid improve-
ments in hyperglycemia observed after bariatric/metabolic surgery.
 On the other hand, Pories et al.  [17] proposed an alternative hypothesis to explain the 
cause of T2DM in obesity: Fasting hyperinsulinemia would be the initial alteration, and the 
remission of the disease following bariatric surgery may be due to the correction of hyperin-
sulinemia  [17] . The authors hypothesized that a putative diabetogenic signal could have been 
released from the gastrointestinal tract in response to overfeeding and that this factor may 
induce fasting hyperinsulinemia, which in turn blunts the normal insulin response to a meal. 
In spite of insulin resistance, the continuous elevated basal insulin levels determine the 
muscle to take up more glucose than needed or able to be stored. Once in the muscle, glucose 
will have converted into pyruvate with subsequent conversions to lactate and alanine. These 
metabolites represent gluconeogenetic substrates that will have released from the muscle 
and, once reached the liver, will lead to an increased hepatic production of glucose. The high 
levels of fasting glucose and lactate in diabetic patients could be then defined to be a conse-
quence of a ‘vicious Cori Cycle’  [17] . 
 Impairment of the Entero-Insular Axis 
 Unger and Eisentraut  [21] invented in 1969 the concept of the entero-insular axis, which 
refers to the link between the gut and the pancreatic islets. Later, Creutzfeldt  [22] developed 
a concept that the axis encompasses nutrient, hormonal and neural signals from the gut to the 
 Fig. 1. Muscle insulin resistance 
and the ‘twin cycle hypothesis’: 
roles of muscle, liver and pancre-
as in the occurrence of T2DM in 
obesity.  
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beta cells, and defined the hormonal or incretinic part of the entero-insular axis. Incretins are 
gut hormones that are released by the gastrointestinal cells upon the contact with nutrients, 
mainly carbohydrates. At physiological levels these nutrients stimulate insulin secretion in the 
presence of elevated blood glucose levels  [21] . Glucose-dependent insulino-tropic polypeptide 
(GIP) and glucagon-like polypeptide-1 (GLP-1) are the two hormones that meet the criteria for 
incretin definition  [23–25] . GLP-1 is produced by the endocrine L cells from the terminal ileum 
and colon. GLP-1 induces secretion and production of insulin and has been shown to signifi-
cantly improve postprandial glycemic control  [26] . GLP-1 upregulates pancreatic beta cell 
genes, promotes beta cell proliferation and inhibits beta cell apoptosis  [27, 28] . Beyond the 
incretinic effect, GLP-1 inhibits glucagon secretion and gastric emptying  [29, 30] and exerts 
metabolic actions by increasing glyconeogenesis in the liver and skeletal muscle and lipo-
genesis in adipose tissue  [26, 29] . GIP is released by the K-type endocrine cells that are clus-
tered in the duodenum and proximal jejunum as a result of carbohydrate and fat absorption 
 [25, 26] . It seems that the main stimulus for GIP release is the rate of absorption, and not the 
luminal content  [25] . GIP induces glucose-mediated insulin secretion but also stimulates beta 
cell proliferation and inhibits beta cell apoptosis  [29] . It has been demonstrated that 80% of 
the entero-insular effect on insulin secretion is driven by GIP  [31] . GIP acts on the adipose 
tissue as well, stimulating lipoprotein lipase activity and incorporation of fatty acids  [23] . 
 Obesity and T2DM are associated with impairment of the entero-insular axis, defined as 
a reduced capacity of incretins to induce glucose-mediated insulin secretion as a result of a 
meal ingestion  [23, 24] . Impairment of GLP-1 action is caused by a blunted secretion of L cells, 
as observed in early stages of T2DM  [32] . Some studies demonstrated that in patients with 
T2DM there is also a reduced secretion of GLP-1 under basal conditions as well as postpran-
dially  [33, 34] . However, with respect to GIP, it seems that chronic desensitization and down-
regulation of the specific receptors on the pancreatic beta cells are the main incriminating 
factors  [23] . Indeed, GIP levels appear to be normal or slightly elevated in patients with 
obesity and T2DM, both in basal and post-prandial states  [35] . GLP-1 and GIP account for 
approximately 50% of the insulin secretion after a meal, thus implying that the impaired 
incretinic effect in T2DM plays an important role in the development of this disease  [36] . 
 The etiologic mechanism proposed by Pories  [37] and Pories et al.  [38] for the devel-
opment of T2DM development in obese patients implies that metabolic deterioration progress 
as a result of an overstimulation of incretins induced by overeating, leading to hyperinsu-
linemia and insulin resistance. However, this hypothesis is in contrast with the reduction in 
GLP-1 levels and the normal or only slightly elevated GIP levels found in obese T2DM patients. 
 Procedures in Bariatric/Metabolic Surgery 
 A large variety of bariatric/metabolic surgical procedures which are based on restrictive 
or malabsorptive methods or the combination of both has been developed over time. However, 
in the large majority (>95%) of the 468,609 bariatric/metabolic procedures performed 
worldwide in 2013 one of the four following interventions was used: Roux-en-Y gastric 
bypass (RYGB), sleeve gastrectomy, adjustable gastric banding, and biliopancreatic diversion 
(BPD) with or without duodenal switch  [38] . All these procedures are now performed lapa-
roscopically  [39] .The anatomical schemes of these four procedures are depicted in  figure 2 . 
 RYGB is a mixed technique combining both restrictive and malabsorptive mechanisms. 
The procedure consists of creating a small gastric pouch (15–20 ml) and bypassing the gastric 
remnant, duodenum, and proximal small bowel. The gastric pouch is anastomosed to the 
jejunum through a narrow Roux-en-Y gastrojejunal anastomosis. In order to restore the 
continuity of the bowel, an entero-entero anastomosis between the excluded biliopancreatic 
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limb and the alimentary limb is performed usually 75–100 cm distal from the gastrojeju-
nostomy  [40, 41] . 
 Sleeve gastrectomy is based on the resection of the main part of fundus and corpus of the 
stomach, starting 2–8 cm proximally to the pylorus until the Angle of His. This procedure was 
created as the first step in a two-staged approach applied in those super-super obese patients 
in whom the execution of a laparoscopic BPD or RYGB was technically extremely difficult to 
perform in one single time. However, significant weight loss and metabolic control was 
observed after sleeve gastrectomy alone, and therefore the method has become very popular 
as an isolated procedure  [39–41] . 
 Adjustable gastric banding is a purely restrictive procedure and involves encircling the 
upper part of the stomach with a silicone adjustable band with an inflatable balloon at the 
inner surface connected with a port place subcutaneously, through which the size of the 
stoma can be adjusted by adding or retracting fluid  [40, 41] . 
 Finally, BPD is a primarily malabsorptive procedure consisting in a horizontal gastrectomy 
and an anastomosis between the remnant stomach and the distal 250 cm of small intestine. 
The bypassed duodenum, jejunum, and part of the proximal ileum carry bile and pancreatic 
secretions and are connected to the alimentary channel 50 cm proximal to the ileocecal valve. 
The ‘common limb’ is the only segment where fat and starches are absorbed  [40, 41] .
 Apart from these four major interventions, several other bariatric/metabolic procedures 
have been invented and proposed. Some of them disappeared because of poor results or high 
rates of complications and failures, and some others are still currently under scrutiny. In 
particular, laparoscopic greater curvature plication is a new restrictive bariatric surgery in 
which the greater curvature of the stomach is folded inward, creating a narrow gastric tube 
without involving gastric resection. Beyond significant weight loss, it seems that this tech-
nique holds metabolic effects as well  [42, 43] . 
 How Does It Work on Type 2 Diabetes? 
 As reported before, the observation that very rapid improvements in blood glucose levels 
and glucose homeostasis occurred within days after bariatric/metabolic surgery long before 
substantial weight loss, initially suggested that other mechanisms beyond weight reduction 
 Fig. 2. Characteristics of the more diffused bariatric/metabolic surgical procedures. From left to right: RYGB, 
sleeve gastrectomy, adjustable gastric banding, BPD with duodenal switch. 
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might be involved in these changes  [13] . Some putative mechanisms can be related to the 
etiologic theories for T2DM briefly summarized in the first part of this review. In particular, 
attention has been focused on the role of surgical food intake restriction and on the changes 
in the release of gastrointestinal hormones ( fig. 3 ). 
 Surgical Restriction of Food Intake – Return to Normal Hepatic Insulin Sensitivity 
 The importance of restriction of food intake in T2DM reversal after surgery was explained 
by Taylor et al.  [15, 16] on the basis of the first steps of the disease development as suggested 
in their etiologic theory: the ‘twin cycle hypothesis’. Indeed, the restriction of caloric intake 
immediately after bariatric surgery is sudden and profound. In case of rapid food shortage, 
the human body is forced to use other internal sources of energy: the triglyceride stores. In 
conditions of hypocaloric intake, ectopic fat from the liver and other depots, including 
pancreatic fat, are mobilized and utilized first  [13, 15] . It has been demonstrated that fasting 
plasma glucose improves in 81% of patients simply because of a decrease in liver fat content 
and normalization of hepatic insulin sensitivity, without any change in insulin resistance at 
the level of skeletal muscle  [15] . Therefore, it could be expected that remission of T2DM after 
surgery might be related to removal of liver and pancreatic fat as a response to severe caloric 
restriction. Taylor et al.  [15, 16] suggested therefore that acute negative calorie balance is all 
that is needed to reverse T2DM after bariatric/metabolic surgery.
 The importance of energy restriction for the rapid improvement of glucose homeostasis 
in the first days after bariatric surgery is supported by the results of several studies exam-
ining the metabolic effects of nonsurgical caloric restriction. Isbell et al.  [44] compared the 
metabolic changes occurring in the first week after RYGB with those observed in a group of 
matched obese patients following the same postoperative liquid diet, but not having had 
RYGB. With only minimal and similar levels of weight loss, a 25% improvement in insulin 
sensitivity was observed both in the RYGB group and in the calorie-matched nonsurgical 
subjects  [44] . Edholm et al.  [45] demonstrated a 12% reduction of liver volume in 15 obese 
female candidates to laparoscopic RYGB treated preoperatively with a 4-week low-calorie 
diet. A mean 14.7% reduction of liver volume and a 47% reduction of liver fat content were 
also observed in 18 patients after a 6-week very low-energy diet  [46] . Finally, Colles et al.  [47] 
 Fig. 3. Mechanisms involved in 
obesity and T2DM and the effects 
of metabolic surgery. 
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found a 28.7% reduction in the liver volume after 12 weeks using the same type of diet, and 
they reported that 80% of the liver volume reduction occurred in the initial 2 weeks. In 
summary, these experimental evidences suggest that rapid improvements of glucose homeo-
stasis and insulin resistance similar to those observed after bariatric/metabolic surgery 
might be obtained also in a nonsurgical setting by exposing obese patients to a similar degree 
of severe calorie restriction, and that these improvements are associated to significant reduc-
tions in liver volume and fat content. Additionally, Lim et al.  [48] analyzed 11 people with 
obesity and T2DM before and after a 600 kcal/day diet by measuring basal hepatic glucose 
output, hepatic and peripheral insulin sensitivity, beta cell function, and pancreas and liver 
triacylglycerol content. After 1 week of restricted energy intake, fasting plasma glucose 
normalized, insulin suppression of hepatic glucose output improved, and hepatic and 
pancreatic triacylglycerol content was reduced. During the same period, the first-phase 
insulin response increased and approached control values  [48] .
 Therefore, normalization of both beta cell function and hepatic insulin sensitivity in 
T2DM can be achieved by dietary energy restriction alone, and this was associated, according 
to the ‘twin cycle hypothesis’, with decreased pancreatic and liver triacylglycerol stores  [15, 
16] . No other metabolic mechanisms beyond food restriction seem therefore necessary to 
explain the rapid postoperative metabolic improvements.
 Reduction of Hyperinsulinemia – a Primary Metabolic Change That Occurs in Response to 
Gastric Bypass Surgery 
 According to the etiologic hypothesis for T2DM proposed by Pories et al.  [17] that fasting 
hyperinsulinemia triggered by the secretion, in response to overfeeding, of a gastrointestinal 
diabetogenic signal is the first lesion in T2DM, the immediate normalization of fasting insulin 
occurring after gastric bypass could be considered the cornerstone for the rapid amelioration 
of T2DM. More importantly, these improvements are independent of changes in weight loss, 
insulin sensitivity, glucose, or free fatty acids. Indeed, the authors speculated that the exclusion 
of foregut leads to the removal of the hyperinsulinemic signal and consequently to less gluco-
neogenic substrate production and resolution of hyperglycemia  [17] . This concept was 
supported by Reed et al.  [49] . These authors studied obese non-diabetic and obese diabetic 
patients receiving gastric bypass and demonstrated that 1 week after surgery fasting insulin 
decreased to levels similar to lean controls and that T2DM remitted despite continued insulin 
resistance. The authors concluded that correction of hyperinsulinemia occurs mainly as the 
consequence of the exclusion of food from the foregut  [49] . 
 The Upper Intestinal Hypothesis  
 The upper intestinal hypothesis, which is known also as ‘the foregut hypothesis’, suggests 
that excluding the duodenum and proximal jejunum from contact with nutrients may avoid 
the over-secretion of a signal that damages glucose homeostasis, promoting decreased 
insulin action, impaired insulin secretion, and finally T2DM onset  [50, 51] . According to this 
theory, an ‘anti-incretinic’ factor should be overproduced in the duodenum of patients with 
obesity and T2DM, counterbalancing the gut incretins production, which, on the other hand, 
is impaired in obese patients with T2DM  [52] . The theory has been proposed by Rubino and 
Gagner  [51] who consequently developed the duodenal-jejunal bypass (DJB), a metabolic 
surgical procedure in which the stomach was left intact, but the same amount of proximal 
intestine as in the classical RYGB was bypassed with a Roux-en-Y gastrojejunostomy. This 
procedure was applied in non-obese and obese diabetic rats, demonstrating a significant 
improvement in blood glucose levels, in theory without any forced food restriction or weight 
loss  [53–55] . In a study on humans, Cohen et al.  [56] reported on two patients with T2DM 
who underwent a DJB and experienced normoglycemia without any weight loss in either 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
ita
 d
i P
ad
ov
a 
   
   
   
   
   
   
   
   
   
   
   
 
14
9.
12
6.
78
.1
7 
- 1
2/
9/
20
15
 1
:4
4:
06
 P
M
357Obes Facts 2015;8:350–363
 DOI: 10.1159/000441259 
 Cătoi et al.: Metabolic Mechanisms in Obesity and Type 2 Diabetes: Insights from 
Bariatric/Metabolic Surgery 
www.karger.com/ofa
© 2015 S. Karger GmbH, Freiburg
patient. However, the putative diabetogenic or anti-incretin gastrointestinal hormones 
being the cornerstone of the Pories et al. [17] and the foregut hypothesis have not been iden-
tified so far.
 The Lower Intestinal Hypothesis 
 The lower intestinal hypothesis, termed also as ‘hindgut hypothesis’, states that the rapid 
delivery of nutrients into the distal bowel, as a consequence of intestinal bypass (duodenum 
and jejunum), brings about an increased secretion of GLP-1 and other incretins, thereby 
leading to an improvement of glucose homeostasis  [13, 57, 58] . These results are believed not 
to be a consequence of weight loss  [24] . RYGBP and BPD are the two bariatric/metabolic 
procedures that more frequently lead to normal concentrations of plasma glucose, insulin 
and glycosylated hemoglobin in morbidly obese diabetic patients  [1] . After BPD, food is 
delivered directly from the stomach to the ileum, and the procedure is followed by very high 
rates of postprandial GLP-1 secretion in plasma  [58] . In RYGP, the intestinal bypass is less 
long, but although only a short segment of the upper intestine is excluded, there is a signif-
icant increase in the meal-stimulated GLP-1 secretion after RYGB, implying that patients who 
undergo this procedure show an increased incretin effect  [58, 59] . An increase GLP-1 secretion 
after meals has never been demonstrated after adjustable gastric banding, a procedure that 
does not involve any modification of the gastrointestinal tract and that has a less intense 
effect on T2DM  [60, 61] . The hindgut hypothesis is further supported by the results observed 
after ‘ileal interposition’, an experimental metabolic procedure in which a segment of ileum 
rich in L cells producing GLP-1 is surgically interposed into the proximal intestine, near the 
duodenum-jejunum boundary. The exposure of the interposed ileum to ingested nutrients 
leads to increased GLP-1 release after meal and improves metabolic outcomes  [58] . On the 
other hand, experimental RYGB produces the same amount of body weight and fat mass loss 
in GLP-1 receptor-deficient mouse, in which the endogenous GLP-1 cannot exert any effect, 
as in wild-type animals  [62] . This new observation poses some doubts on an important indi-
vidual role of GLP-1 or any other single gastrointestinal hormone in the mechanisms by which 
RYGB exerts its beneficial effects and suggest that more complex and integrated mechanisms 
are involved. 
 As stated before, pure restrictive bariatric procedures, such as the adjustable gastric 
banding, do not alter postprandial incretin levels  [60, 61] . Sleeve gastrectomy has been for a 
long-time considered a pure restrictive procedure and does not involve any change in the 
continuity of the gastrointestinal tract. However, sleeve gastrectomy has been shown to 
produce rapid improvements in glucose homeostasis and is followed by significant changes 
in gastrointestinal hormones similar to those observed after in RYGB: reduced ghrelin 
secretion and increased GLP-1 synthesis  [63] . Reduced ghrelin secretion can be obviously 
explained by the gastric fundus resection, but the reason for increased GLP-1 production 
remains more elusive. A possible explanation is that GLP-1 release might be triggered not 
only by the direct contact of distal L cells with indigested food but also by proximal nutrient 
signals, e.g., increased cholecystokinin (CCK) secretion. The authors concluded that neither 
the upper nor the lower intestinal hypothesis can fully account for improvement in glucose 
homeostasis, suggesting that rather the balance between foregut (ghrelin, CCK) and hindgut 
hormones (GLP-1, PYY) could be the key for a better understanding of the improved glucose 
homeostasis  [63] . In this respect, increased attention has been reserved to a possible role of 
bile acids (BAs) and gut microbiota.
 Bile Acid Changes after Bariatric Surgery 
 Emerging data demonstrate that beyond their role in absorption of fats, fat-soluble 
vitamins and cholesterol, BAs are important key regulators of glucose and lipid metabolism 
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and energy expenditure, being involved in prevention of obesity, insulin resistance, T2DM, 
and the metabolic syndrome  [64, 65] . Primary BAs are produced form cholesterol in the liver. 
Most of them are conjugated with taurine and glycine, stored in the gallbladder, and finally 
secreted upon meal stimulation into the duodenum, where they mix with fatty acids and 
contribute to the digestion of lipids and lipid-soluble vitamins. Some primary BAs are trans-
formed into secondary BAs by gut microbiome. In the terminal ileum BAs are absorbed, flow 
back to the liver and are secreted again into the bile in the enterohepatic cycle  [64–66] . Known 
as signaling molecules, BAs mediate most of their beneficial effects on metabolism by inter-
action with the nuclear hormone receptor farnesoid X receptor (FXR) and the membrane 
receptor G-protein-coupled BA receptor 5 (TGR5)  [67] . Briefly, BAs inhibit gluconeogenesis 
 [68] and promote insulin signaling and glycogen synthase activation, thus favoring insulin-
dependent control of glucose metabolism in the liver  [69, 70] . Through intestinal FXR, BAs 
stimulate postprandial fibroblast grow factor 19 (FGF19) production in the ileum, which acts 
on hepatocytes through specific receptors to inhibit the expression of cholesterol 7 alpha-
hydroxylase 1 (CYP7A1), thus regulating the conversion of cholesterol into bile acids  [71, 72] . 
BAs act also throughTGR5 and stimulate the release of GLP-1  [65, 67, 73] . This type of action 
of BAs fits somehow into the ‘hindgut hypothesis’, as it has previously been demonstrated in 
a canine model that both food and BAs, on their own, stimulated GLP-1 and peptide YY (PYY) 
responses  [70] .
 In healthy insulin-sensitive individuals, BA levels vary as a consequence of fasting and 
refeeding, with an increase in response to oral glucose load  [74] . However, abnormalities in 
BA levels have been shown in individuals with prediabetes, diabetes, and insulin resistance 
 [75] . Ahmad et al.  [76] demonstrated that, although the fasting circulating BA concentrations 
were not significantly different between lean and obese subjects, patients with obesity had a 
blunted conjugated BA excursion after a meal. In a group of morbidly obese patients with 
diabetes, Gerhard et al.  [77] showed lower FGF19 levels and higher BA levels as compared to 
non-diabetic patients, and this might be most probably due to a lack of response to BAs in the 
liver as well as to the presence of a form of impairment in hepatic response to FGF19. Moreover, 
the authors underlined that the lower levels of FGF19 and the high values of BAs were present 
in patients with T2DM irrespective of BMI  [77] . 
 Several studies have demonstrated that BA levels increased after bariatric surgery, 
mainly after RYGB and sleeve gastrectomy, suggesting that elevated serum BA levels could 
contribute to improvements in insulin sensitivity, incretin secretion, and postprandial 
glycemia  [70, 77–80] . However, by contrast, circulating BAs do not significantly change after 
gastric banding, and this may be due to the fact that in this procedure there is no rear-
rangement of the gastrointestinal tract  [81] . The raise in BAs observed after RYGB is believed 
to be the result of the reduced time for the excreted BAs to mix with food, thereby leaving 
more free BAs for ileal re-uptake  [66] . As ‘digestate-free’ BAs reach rapidly the distal jejunum 
or proximal ileum, which is where FGF19- and GLP1-producing cells are found, they may 
stimulate production of BAs in the liver or insulin in the pancreas  [67] . After sleeve gastrectomy, 
there is a rapid gastric emptying that might generate an uneven distribution of gastric contents 
and bile secretion within the gastrointestinal tract  [64] . The observation that circulating BAs 
increase after RYGB has brought about the assumption that they may contribute to weight-
independent improvements in glucose homeostasis  [82] . However, the data is conflicting. 
While Pournaras et al.  [70] revealed that there is a significant rise in BAs and FGF19 within 
days after RYGB, Steinert et al.  [79] showed that, while the marked increase in GLP-1 and 
peptide YY (PYY) secretion and the improvement in glycemic control were seen already 1 
week and 3 months after surgery, basal and postprandial plasma BA concentrations increased 
much slower, with a significant increase only 1 year post surgery. In conclusion, some data 
suggest that BAs may partly explain the complex metabolic effects seen after bariatric surgery. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
ita
 d
i P
ad
ov
a 
   
   
   
   
   
   
   
   
   
   
   
 
14
9.
12
6.
78
.1
7 
- 1
2/
9/
20
15
 1
:4
4:
06
 P
M
359Obes Facts 2015;8:350–363
 DOI: 10.1159/000441259 
 Cătoi et al.: Metabolic Mechanisms in Obesity and Type 2 Diabetes: Insights from 
Bariatric/Metabolic Surgery 
www.karger.com/ofa
© 2015 S. Karger GmbH, Freiburg
 Bariatric Surgery and Gut Microbiome  
 Recent discoveries have revealed that the gut microbiome is involved in health and 
disease  [83] . Human gut microbiome is very complex and seems to hold a number of cells 
approximately tenfold greater than the rest of the human body combined, with the greatest 
concentration in the ileum and colon  [64, 84, 85] . Studies have shown that the human gut 
microbiome is composed primarily of the phyla Bacteroidetes and Firmicutes. Gut microbiota 
interacts with the host in several ways including i) modulation of the inflammatory host 
response; ii) synthesis of small molecules and proteins that are taken up by the host; and iii) 
changes in the amount of available energy in the diet  [85] . The gut microbiome has emerged 
as an important contributor to the obesity and T2DM epidemic and is proposed to act by 
increasing energy harvest from the diet, by altering metabolic and appetite signaling pathways 
and by inducing chronic inflammation  [86–88] . However, the precise pathophysiology of gut 
microbiome in obesity remains only partly understood  [86] . Some findings have shown that 
in the gut of obese humans and mice, the ratio of Firmicutes to Bacteroidetes is elevated and 
falls with weight loss  [89] .
 Bariatric surgery not only improves hormonal and inflammatory status but also induces 
numerous changes in the digestive tract that might account for some modifications of micro-
biome ecology  [90] . Thereby, several studies have examined the role of the distal gut micro-
biome in obesity and the changes that occur after RYGB in humans and rodents  [85] . One 
study showed that the transfer of the microbiota from RYGB-treated mice to germ-free mice 
resulted in weight loss, indicating that changes in the gastrointestinal microbiome following 
surgery may contribute to weight loss  [91] . On the other hand, changes in the composition of 
gut microbiome with important effects on the metabolism have been reported after RYGB. 
More precisely, a decrease in the Firmicutes:Bacteroides ratio  [92, 93] and an increase in the 
bile-tolerant Proteobacteria  [93–95] have been described. These changes might be partly 
explained by the changes in the diet  [96] . Moreover, there seems to be a complex relationship 
between gut microbiome and BAs. The presence of a higher amount of free BAs in the lower 
intestine creates an environment encouraging the growth of the  Proteobacter phylum  [97] . In 
turn,  Proteobacter causes a decrease in secondary BAs, leading to increased serum primary 
BA levels  [97] . Taken together, these data suggests that the rerouting of the intestinal anatomy, 
and the changes of gut microbiome and BA levels that are brought about, may improve 
systemic metabolism through complex mechanisms. 
 Conclusions 
 A large and exhaustive meta-analysis recently confirmed that bariatric/metabolic surgery 
has a greater weight loss effect and a higher rate of T2DM remission than conventional 
therapy  [12, 98] . Although metabolic surgery involves an initial financial investment, the use 
of this type of interventions in T2DM obese patients, who otherwise imply important health 
costs, may be associated with important savings in a relatively short period of time  [99] , and 
the costs of antidiabetic drugs 2 years after surgery is estimated to be 79% lower than before 
the operation  [100] . 
 Most of the benefits of bariatric/surgery can be attributed to weight loss, especially in the 
long term. However, some important clinical improvements, in particular in respect to glucose 
homeostasis and T2DM occur independently from weight loss levels, suggesting that alter-
native mechanisms may play a role. The uncertainty that we still have about what these mech-
anisms are and to which extent they contribute to the effects detected is reflected in our 
incomplete understanding about the etiologic mechanisms of T2DM in obesity. Surgical food 
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restriction is certainly important, but, depending on the type of rearrangements of the gastro-
intestinal tract, other weight-independent antidiabetic mechanisms can be involved, such as 
the incretinic/anti-incretinic system and possibly even more other pathways. At the end, 
bariatric/metabolic surgery remains a complex subject of research, and the elucidation of its 
mechanisms of action can help to clarify the still elusive pathophysiology of T2DM in obesity. 
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